威海治疗癫痫病专业医院(威海治小儿羊羔疯好的医院) (今日更新中)

WASHINGTON, Aug. 2 (Xinhua) -- The weakness of aging is associated with leaky calcium channels inside muscle cells and a drug already in Phase II clinical trials for the treatment of heart failure might plug those leaks, according to a report published Tuesday in the online edition of Cell Metabolism.Earlier studies by the research team led by Andrew Marks of Columbia University showed the same leaks underlie the weakness and fatigue that come with heart failure and Duchenne muscular dystrophy."It's interesting, normal people essentially acquire a form of muscular dystrophy with age," Marks said. "The basis for muscle weakness is the same." Extreme exercise like that done by marathon runners also springs the same sort of leaks, he added, but in that case damaged muscles return to normal after a few days of rest. A microscopic view shows smooth muscle cells derived from human embryonic stem cells showing the nuclei (blue) and proteins of the cytoskeleton (green) in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009The leaks occur in a calcium release channel called ryanodine receptor 1 (RyR1) that is required for muscles to contract. Under conditions of stress, those channels are chemically modified and lose a stabilizing subunit known as calstabin1.Calcium inside of muscle cells is usually kept contained. When it is allowed to leak out into the cell that calcium itself is toxic, turning on an enzyme that chews up muscle cells. Once the leak starts, it's a vicious cycle. The calcium leak raises levels of damaging reactive oxygen species, which oxidize RyR1 and worsen the leak.The researchers made their discovery by studying the skeletal muscles of young and old mice. They also showed that 6-month-old mice carrying a mutation that made their RyR1 channels leaky showed the same muscular defects and weakness characteristic of older mice.When older mice were treated with a drug known as S107, the calcium leak in their muscles slowed and the animals voluntarily showed about a 50 percent increase in the amount of time spent wheel running. Now in clinical trials for patients with heart failure, the drug is known to work by restoring the connection between costabilin and RyR1.Despite considerable effort to understand and reverse age- related muscle wasting, there are no established treatments available. The new work suggests there may be hope in approaching the problem from a different angle."Most research has focused on making more muscle mass," Marks said. "What's different here is that we are focused not on muscle mass but on muscle function. More muscle doesn't help if it is not functional."

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

BEIJING, Aug. 24 (Xinhuanet)-- A new study shows that a diet rich in cholesterol-friendly foods, such as soy products and tree nuts, can decrease LDL (bad) cholesterol significantly, according to media reports on Tuesday.The study, published in the Journal of the American Medical Association, found that people who ate a healthy diet filled with cholesterol-lowering foods experienced a 13 percent decrease in their LDL cholesterol levels.For patients with high levels of so-called bad cholesterol, doctors usually have two prescriptions: cholesterol-lowering statin drugs and a diet that cuts out foods high in saturated fat, such as ice cream, red meat and butter.But the new study found that when it comes to lowering artery-clogging cholesterol, what you eat may be more important than what you don't eat.David Jenkins of St. Michael's Hospital and the University created the "portfolio diet," which includes regular consumption of tree nuts and high amounts of fiber from oats, barley and vegetables. The diet, which replaces butter with plant sterol-enriched margarine and substitute soy-based products for meat, allows maximum benefit in lowering cholesterol and preventing heart disease. "The study highlighted the power of food to lower risk for cardiovascular disease: What you do eat and what you don't eat are both important," said Dr. Jane Klauer, a New York internist specializing in metabolism and nutrition.A high overall cholesterol level makes a person nearly twice as likely to suffer a heart attack or stroke as someone whose total cholesterol falls into a healthy range.

来源：资阳报